Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07175428 · ClinicalTrials.gov registry record · Phase 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

A Phase 2 study of Atrial Fibrillation (AF), sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
1,200
Enrollment target
20
Study locations

NCT07175428 is a Phase 2 study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,200 participants, above the 649-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (85% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07175428, a Phase 2 study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
1,200 participants
Enrollment target
20
Study locations

Study Summary

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Conditions Studied

Atrial Fibrillation (AF)

Interventions

  • DRUG Apixaban
  • DRUG REGN7508
  • DRUG REGN9933

Study Locations (20)

California

  • Mission Cardiovascular Research Institute - Fremont
  • National Institute of California Heart and Vein Specialists - Huntington Beach
  • Profound Research LLC at Southern California Heart Specialists - Pasadena
  • Empire Clinical Research - Pomona
  • Northbay Clinical Research Center - Santa Rosa
  • Cardiology Associates Medical Group - Ventura
  • Interventional Cardiology Medical Group - West Hills

Florida

  • Nouvelle Clinical Research LLC - Cutler Bay
  • Inpatient Research Clinic LLC - Miami Lakes
  • Cardiovascular Center of Sarasota Foundation for Research and Education - Sarasota
  • Clinical Site Partners, LLC DBA Flourish Research - Winter Park

Indiana

  • Indiana University - Indianapolis
  • Blue Coast Research Center, LLC - Indianapolis
  • Franciscan Physician Network, Indiana Heart Physicians - Indianapolis
  • Reid Physician Associates - Richmond

Alabama

  • SEC Clinical Research - Dothan
  • Eastern Shore Research Institute - Fairhope

Georgia

  • Health Sciences Research Building II - Atlanta
  • NSC Research, Inc - Johns Creek

Louisiana

  • Monroe Research, LLC - West Monroe

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2025-10-20
Est. Completion 2027-04-21
Phase Phase 2

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07175428

The ClinicalTrials.gov registry entry for NCT07175428 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 649-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (85% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 3 interventions - of which Apixaban is the first listed.

NCT07175428 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT07175428 about?

NCT07175428 is a clinical study titled "Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation". This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillati...

What is the current status of trial NCT07175428?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,200 participants. The study started on 2025-10-20. Estimated completion is 2027-04-21.

What conditions does trial NCT07175428 study?

This clinical trial studies the following conditions: Atrial Fibrillation (AF).

What interventions are being tested in trial NCT07175428?

The interventions under investigation include: Apixaban (DRUG), REGN7508 (DRUG), REGN9933 (DRUG).

Who is sponsoring clinical trial NCT07175428?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07175428 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation (AF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation (AF)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.